Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Cavender

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
European Heart Journal. Acute Cardiovascular Care|October 17, 2014
The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trialMatthew A Cavender, C Michael Gibson, Eugene Braunwald, et al.
American Heart Journal|September 11, 2021
Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trialMatthew A Cavender, Michelle L O'Donoghue, Antonio Abbate, et al.
Circulation|February 15, 2015
Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trialMatthew A Cavender, Benjamin M Scirica, Marc P Bonaca, et al.
The American Journal of Medicine|November 3, 2015
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1cMatthew A Cavender, Benjamin M Scirica, Itamar Raz, et al.
JAMA Cardiology|September 30, 2016
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical TrialBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Journal of the American College of Cardiology|June 2, 2018
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REALMatthew A Cavender, Anna Norhammar, Kåre I Birkeland, et al.
American Heart Journal|May 13, 2015
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trialMichelle L O'Donoghue, Ruchira Glaser, Philip E Aylward, et al.
Circulation|May 20, 2017
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, et al.
Diabetes, Obesity & Metabolism|March 24, 2018
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL studyMikhail Kosiborod, Kåre I Birkeland, Matthew A Cavender, et al.
Journal of the American College of Cardiology|November 10, 2012
Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarctionAndrew N Rassi, Matthew A Cavender, Gregg C Fonarow, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
European Heart Journal. Acute Cardiovascular Care|October 17, 2014
The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trialMatthew A Cavender, C Michael Gibson, Eugene Braunwald, et al.
American Heart Journal|September 11, 2021
Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trialMatthew A Cavender, Michelle L O'Donoghue, Antonio Abbate, et al.
Circulation|February 15, 2015
Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trialMatthew A Cavender, Benjamin M Scirica, Marc P Bonaca, et al.
The American Journal of Medicine|November 3, 2015
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1cMatthew A Cavender, Benjamin M Scirica, Itamar Raz, et al.
JAMA Cardiology|September 30, 2016
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical TrialBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Journal of the American College of Cardiology|June 2, 2018
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REALMatthew A Cavender, Anna Norhammar, Kåre I Birkeland, et al.
American Heart Journal|May 13, 2015
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trialMichelle L O'Donoghue, Ruchira Glaser, Philip E Aylward, et al.
Circulation|May 20, 2017
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, et al.
Diabetes, Obesity & Metabolism|March 24, 2018
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL studyMikhail Kosiborod, Kåre I Birkeland, Matthew A Cavender, et al.
Journal of the American College of Cardiology|November 10, 2012
Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarctionAndrew N Rassi, Matthew A Cavender, Gregg C Fonarow, et al.
Pageof 9